Moderna Inc. and the future of vaccine technologies : management and protection of intellectual property / Alan Trinh.

Format:

Book

Author/Creator:

Trinh, Alan, author.

Series:

SAGE business cases.

SAGE business cases

Language:

English

Subjects (All):

Intellectual property--Case studies.

Intellectual property.

Vaccines--Case studies.

Vaccines.

Physical Description:

1 online resource.

Place of Publication:

London : SAGE Publications: SAGE Business Cases Originals, 2022.

Summary:

At the beginning of the COVID-19 pandemic, Moderna Inc. jumped into the pharmaceutical race for a vaccine. Moderna Inc., a biotech pharmaceutical company founded in 2010 in Cambridge, Massachusetts, focuses on research and manufacturing vaccines using messenger RNA (mRNA) technology. As the pandemic continues, Moderna faces issues regarding its intellectual property and patents. Moderna must find strategies to manage and protect their intellectual properties in a focused niche of mRNA vaccines and therapeutics while balancing their ethical obligation to help as many people as possible as quickly as possible. Students are invited to think through various tactics that Moderna Inc. can use to manage and protect its intellectual property and determine an optimal strategy for the company post-pandemic.

Notes:

Includes bibliographical references and index.

Description based on XML content.

ISBN:

1-5297-9320-3

9781529793208

OCLC:

1290779171